MicroRNA-615-3p decreases apo B expression in human liver cells.

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Plasma lipids are transported by apolipoprotein B (apoB)-containing lipoproteins.
• Elevated apoB levels are linked to metabolic diseases and atherosclerotic cardiovascular disease.
• MicroRNAs (miRs) are regulators of gene expression with therapeutic potential.

Purpose of the Study:

• To identify novel microRNAs regulating apolipoprotein B (apoB) expression.
• To investigate the role of miR-615-3p in apoB regulation and lipoprotein metabolism.
• To explore the therapeutic potential of targeting miR-615-3p for metabolic and cardiovascular diseases.

Main Methods:

• Identification of miR-615-3p using bioinformatics and cell-based assays.
• Luciferase reporter assays to confirm interaction between miR-615-3p and apoB mRNA 3'-UTR.
• CRISPR-sgRNA technology to modulate endogenous miR-615-3p levels.
• Overexpression studies of miR-615-3p in human hepatoma Huh-7 cells.
• Measurement of cellular and secreted apoB100, triglycerides, and endoplasmic reticulum stress markers.

Main Results:

• miR-615-3p directly targets the 3'-UTR of apoB mRNA, inducing degradation and reducing apoB100 levels.
• Downregulation of endogenous miR-615-3p using CRISPR-sgRNA increased apoB100 expression.
• Overexpression of miR-615-3p decreased cellular and secreted apoB, and increased cellular triglycerides without ER stress.
• miR-615-3p acts as a negative regulator of apoB expression in human liver cells.

Conclusions:

• miR-615-3p is a novel regulator of apolipoprotein B (apoB) expression in human liver-derived cells.
• Modulating miR-615-3p levels presents a potential therapeutic strategy for managing apoB-related metabolic and cardiovascular diseases.
• Further discovery of miRs regulating apoB may reveal new mechanisms in lipoprotein assembly and secretion.